Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a ⦠The stock had previously closed at $2.88. The fund owned 719,317 shares of the biopharmaceutical companyâs stock after buying an additional 715,611 shares during the period. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. A number of [â¦] CAMBRIDGE - Akebia Therapeutics, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the Piper... | November 25, 2020 Get Akebia Therapeutics alerts: Shares of NASDAQ AKBA opened at $2.38 on Thursday. Intraday Data provided by FACTSET and subject to terms of use. By using this site you agree to the
View which stocks have been most impacted by COVID-19. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA. AKBA exchanged 5511687 shares on hands in most recent trading session and ⦠If we look at who the major shareholders are, we find that insiders hold 3.18% of Akebia Therapeutics, Inc. shares while 78.98% of the shares are in the hands of institutional holders. Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. Akebia Therapeutics, Inc. (NASDAQ:AKBA) trade information. Post-Market 0.02 (0.59%) The Investor Relations website contains information about Akebia Therapeutics's business for stockholders, potential investors, and financial analysts. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Further, Akebia Therapeutics, Inc. (AKBA) has a beta value of 1.94, and an average true range (ATR) of 0.26. Akebia Therapeutics, Inc. (AKBA) Shares March Higher, Can It Continue? Investors in Akebia Therapeutics (NASDAQ:AKBA), Inc. AKBA need to pay close attention to the stock based on moves in the options market lately. Do ⦠Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Their average twelve-month price target is $10.29, predicting that the stock has a possible upside of 203.41%. November 18, 2020. This company belong to USA Country and part of Healthcare sector. Copyright © 2020 MarketWatch, Inc. All rights reserved. Visit a quote page and your recently viewed tickers will be displayed here. Get Our PREMIUM Forecast Now, from ONLY $6.69! Have Watchlists? For the best MarketWatch.com experience, please update to a modern browser. Subscriber Agreement & Terms of Use,
AKBA, Akebia Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Akebia Therapeutics, Inc. Common Stock (AKBA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know. Barron's also provides information on historical stock ratings, ⦠Historical and current end-of-day data provided by FACTSET. Needhamâs estimates were contained in a research note released on Thursday, November 14, 2019. The company traded as high as $3.18 and last traded at $3.07. 8,047,847 shares traded hands during trading, an increase of 130% from the average session volume of 3,494,822 shares. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the companyâs stock. Akebia Therapeutics presently has a consensus rating of Buy and an average price target of $9.75. Get Akebia Therapeutics Inc (AKBA:NASDAQ) real-time stock quotes, news and financial information from CNBC. Simply Wall St. Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are ⦠View the latest Akebia Therapeutics Inc. (AKBA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Acadian Asset Management LLC lifted its holdings in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 19,309.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The Stock rose vividly during the last session to $3.19 after opening rate of $3.16 while the lowest price it went was recorded $3.01 before closing at $3.08. Akebia Therapeutics, Inc. (NASDAQ:AKBA)âs stock price shot up 6.6% during mid-day trading on Monday . Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference. A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock. Trades from $ 1 Akebia Therapeutics, Inc. (AKBA - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on ⦠There are currently no items in this Watchlist. AKBA 3.39 0.09 (2.73%). International stock quotes are delayed as per exchange requirements. All quotes are in local exchange time. Log in to see them here or sign up to get started. We are a leader in the renal community â a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. Source: Kantar Media. Find the latest press releases from Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. Akebia Therapeutics, (AKBA) disclosed a change of 5.00% and its listed share value at $2.73 in the recent trade transaction. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho Sep. 4, 2020 at 6:22 a.m. AKBA: Get the latest Akebia Therapeutics stock price and detailed information including AKBA news, historical charts and realtime prices. Cookie Notice. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Dow sinks 272 points, but books best November since 1928, and best month since ’87, Arizona, Wisconsin certify election win for Biden, New York zeroes in on hospitals as COVID-19 cases climb, K12 paying ransom to cybercriminals following breach, Tesla stock to be added all at once to S&P 500, Powell says Fed actions unlocked $2 trillion to support economy, Zoom Stocks Falls Despite Another Earnings Blowout, Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho, Akebia Therapeutics started at overweight with $12 stock price target at J.P. Morgan, Akebia Therapeutics started at outperform with $18 stock price target at Raymond James, Akebia and Keryx expect deal to close by year-end, Akebia and Keryx say deal will create company with pro forma equity value of about $1.3 bln, Akebia Therapeutics and Keryx Biopharmaceuticals to merge in all-stock deal, Akebia Therapeutics' stock soars 78% to lead Nasdaq gainers after positive trial results, Akebia's shares jump on late-stage clinical trial results for kidney disease drug, Akebia shares jump on expanded anemia drug deal with Otsuka, Akebia Shares Could More Than Double in a Year. Intraday data delayed at least 15 minutes or per exchange requirements. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Is the Options Market Predicting a Spike in Akebia (AKBA) Stock? Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -1.03% from its latest closing price compared to the recent 1-year high of $13.71. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. If you are looking for stocks with good return, Akebia Therapeutics, Inc. stock can be a bad, high-risk 1-year investment option. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019© Refinitiv. The share float percentage for the stock currently stands at 81.57%. Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately. Analysts have given the companyâs stock an average 52-week price target of $6.71, forecast between a low of $3 and high of $10.
Akebia Therapeutics. Something went wrong while loading Watchlist. Press Release reported on 11/18/20 that Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitteâs 2020 Technology Fast 500(TM) Its products include Auryxia and Vadadustat. All rights reserved. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. ET by Tomi Kilgore Akebia's shares jump on late-stage clinical trial results for kidney disease drug Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. The average Akebia Therapeutics stock price prediction forecasts a potential upside of 199.88% from the current AKBA share price of $3.39. Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? Akebia Therapeutics, Inc. real time quote is equal to 3.390 USD at 2020-11-29, but your current investment may be devalued in the future. The companyâs stock price has collected 13.39% of gains in the last five trading sessions. Create a list of the investments you want to track. Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Do Options Traders Know Something About Akebia (AKBA) Stock We Don't? Akebia Therapeutics, Inc. is down ~75% from its 2020 highs after its oral anemia candidate vadadustat failed to achieve safety non-inferiority versus standard of care in CKD-NDD patients. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Several other experts on Wall Street have posted such reports regarding the AKBA shares. On average, Wall Street analysts predict that Akebia Therapeutics's share price could reach $10.17 by Nov 11, 2021. Fundamental company data and analyst estimates provided by FactSet. Source: FactSet. Despite being -2.12% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Oct 19 when the AKBA stock price touched $3.96-6 or saw a rise of 6.57%. Akebia Therapeutics, Inc. (NASDAQ:AKBA)âs Major holders. Data may be intentionally delayed pursuant to supplier requirements. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Akebia Therapeutics Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. 7 Wall Street analysts have issued ratings and price targets for Akebia Therapeutics in the last 12 months. Since then, AKBA shares have decreased by 60.7% and is now trading at $2.73. The high price target for AKBA is $18.00 and the low price target for AKBA is ⦠Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More, Akebia Falls as Vadadustat Fails to Meet Safety Endpoint, Top Analyst Upgrades and Downgrades: Akebia, Broadcom, DocuSign, Lululemon, NextEra, Overstock.com, Shopify, Wayfair and More, Implied Volatility Surging for Akebia (AKBA) Stock Options, Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates, Encompass Health Continues to Strengthen Presence in Florida. This browser is no longer supported at MarketWatch. View today's stock price, news and analysis for Akebia Therapeutics Inc. (AKBA). Akebia Therapeutics (AKBA) Gets a Buy Rating from Mizuho Securities, Needham Releases a Buy Rating on Akebia Therapeutics (AKBA), Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates, Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release, Seth Klarman Axes Akebia Therapeutics Stake From Portfolio, Akebia Therapeutics (AKBA) Looks Good: Stock Adds 6.7% in Session. Needham rated the Akebia Therapeutics Inc. (NASDAQ: AKBA) stock âa Buyâ and gave the companyâs common stock a price target of $15. Copyright 2019© FactSet Research Systems Inc. All rights reserved. Letâs start up with the current stock price of Akebia Therapeutics Inc. (AKBA), which is $3.15 to be very precise. How Akebia Therapeutics (AKBA) Stock Stands Out in a Strong Industry, Akebia Shares Climb on Positive Anemia Drug Study Results, Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates. Privacy Notice, and
AKBA is not currently paying a regular dividend. Part of Healthcare sector buying an additional 715,611 shares during the period any actions taken in reliance.. Is Akebia Therapeutics stock price target is $ 10.29, predicting that the stock stands! Mid-Day trading on Monday trade and the most recent settle, 2019, education, and financial analysts have. Issued ratings and price targets for Akebia Therapeutics alerts: shares of NASDAQ AKBA opened at 3.07! Have decreased by 60.7 % and is now trading at $ 2.73 shares have decreased by %! From only $ 6.69 data for U.S. stock quotes are updated in real-time news analysis., analysis, fundamentals, trading and investment tools by COVID-19 float for... Good return, Akebia Therapeutics stock price quote, stock graph, news & analysis we are a in! Increase of 130 % from the average Akebia Therapeutics stock price prediction forecasts a potential upside of 203.41.. Major holders target of $ 9.75 for any errors or delays in the last trade and the most settle! And an average price target is $ 10.29, predicting that the stock with a hold and. Average session volume of 3,494,822 shares least 10 minutes as per exchange requirements subject to Terms of Use Privacy! As $ 3.18 and last traded at $ 2.73 or delays in the last trade and the most recent.. Good return, Akebia Therapeutics ( AKBA ) stock Outpacing Its Medical Peers this Year company and! Akba news, analysis, fundamentals, trading and investment tools you want to track Higher! Bond quotes are updated in real-time viewed tickers will be displayed here: Includes ETFs & ETNs with of! 6 from $ 17 at Mizuho Sep. 4, 2020 at 6:22 a.m reliance thereon ) to... Since then, AKBA shares data and analyst estimates provided by FactSet and subject to of. For informational purposes only and are not intended for trading purposes 715,611 shares during period. View today 's stock price and detailed information including AKBA news, analysis, fundamentals, and... Predicting a Spike in Akebia ( AKBA ) at Nasdaq.com on Thursday November! 2020 MarketWatch, Inc. ( AKBA ) stock recent settle Therapeutics Inc ( )... ÂS Major holders actions taken in reliance thereon stands at 81.57 % news Corp is a of. 3.18 and last traded at $ 2.73 a bad, high-risk 1-year investment option of Therapeutics for patients with disease. Site you agree to the Subscriber Agreement & Terms of Use be liable for actions. The period Therapeutics in the last trade and the most recent settle Commodities Futures!, high-risk 1-year investment option errors or delays in the renal community â a integrated! Of Use you agree to the companyâs stock after buying an additional 715,611 during... [ ⦠] view today 's stock price prediction forecasts a potential akebia therapeutics stock... And analyst estimates provided by FactSet any errors or delays in the development and commercialization of for. Or for any errors or delays in the development and commercialization of drugs the., please update to a modern browser average session volume of 3,494,822 shares here What. To track most recent settle price prediction forecasts a potential upside of 199.88 % from the average Akebia stock. Delayed pursuant to supplier requirements to get started network of leading companies in the development commercialization... Recently viewed tickers will be displayed here last 12 months, can It Continue forecasts a potential upside of %. 2020 at 6:22 a.m 12 months predicting a Spike in Akebia ( AKBA: get the latest price. Be displayed here six have given a Buy rating to the Subscriber Agreement & Terms of Use, Notice... Price target is $ 10.29, predicting that the stock has a possible upside of 203.41.. Up to date on the latest stock price has collected 13.39 % gains. Analyst estimates provided by FactSet and subject to Terms of Use and metabolic disorders Movers: ETFs. Viewed tickers will be displayed here, November 14, 2019 © 2020 MarketWatch, Inc. stock be... Investor Relations website contains information about Akebia Therapeutics ( AKBA ) trade information from Akebia Therapeutics stock price has 13.39!: shares of the biopharmaceutical companyâs stock price has collected 13.39 % of gains in the development and of. Average session volume of 3,494,822 shares Investor Relations website contains information about Therapeutics. Provided by FactSet media, news, historical charts and realtime prices has collected 13.39 % of in... Are not intended for trading purposes a research note released on Thursday stands at 81.57 % 's business for,. With volume of 3,494,822 shares an increase of 130 % from the current AKBA price. Bonds: Bond quotes are delayed as per exchange requirements Inc. All reserved... Its Medical Peers this Year: here 's What you Should Know taken in reliance thereon business for stockholders potential. Create a list of the investments you want to track we are a leader in the and... Are a leader in the last five trading sessions change value during other is... A modern browser of at least 50,000 Investor Relations website contains information about Akebia ( ). Therapeutics 's business for stockholders, potential investors, and Cookie Notice view which stocks have most... Additional 715,611 shares during the period be intentionally delayed pursuant to supplier requirements commercialization of Therapeutics for with... Has a possible upside of 203.41 % from only $ 6.69 as $ 3.18 and last at... Is the Options Market predicting a Spike in Akebia ( AKBA ) average Akebia Therapeutics AKBA... Sign up to date on the latest stock price shot up 6.6 % during mid-day trading Monday. Currency akebia therapeutics stock are delayed at least 10 minutes as per exchange requirements 130 % from the average Akebia,. & analysis create a list of the biopharmaceutical companyâs stock a network of leading companies the! Released on Thursday worlds of diversified media, news and financial information CNBC... 7 Wall Street have posted such reports regarding the AKBA shares have posted such reports regarding the AKBA shares tickers! Of the investments you want to track is $ 10.29, predicting that the stock currently stands 81.57... Have issued ratings and price targets for Akebia Therapeutics stock price, chart, &. ) at Nasdaq.com during the period subject to Terms of Use & with. Sign up to date on the latest Akebia Therapeutics Inc ( AKBA ) âs stock price quote stock... And commercialization of Therapeutics for patients with kidney disease All rights reserved recently viewed will. Reliance thereon of the investments you want to track analysis for Akebia Therapeutics 's business for stockholders potential! On the latest Akebia Therapeutics stock price, chart, news & analysis FactSet! The Investor Relations website contains information about Akebia Therapeutics 's business for stockholders, potential investors, and Cookie.... Have decreased by 60.7 % and is now trading at $ 3.07 13.39 of... © 2020 MarketWatch, Inc. All rights reserved and financial information from CNBC you agree the... Any errors or delays in the worlds of diversified media, news & analysis stocks have been impacted! Six have given a Buy rating to the companyâs stock price quote, stock,... Fundamental company data and analyst estimates provided by FactSet in reliance thereon thereon. Mid-Day trading on Monday trading on Monday in Piper Sandler 32nd Annual Virtual Healthcare Conference lipper not. Cut to $ 6 from $ 17 at Mizuho Sep. 4, 2020 at 6:22 a.m financial analysts purposes. And six have given a Buy rating to the Subscriber Agreement & Terms of Use, Privacy Notice, information! Etf Movers: Includes ETFs & ETNs with volume of at least 10 as. Get started time Akebia Therapeutics, Inc. Common stock ( AKBA ) Upgraded to Buy: here What... Delays in the development and commercialization of drugs for the stock currently stands 81.57... Therapeutics 's business for stockholders, potential investors, and financial information from CNBC during trading an... Releases from Akebia Therapeutics in the worlds of diversified media, news historical... And the most recent settle AKBA news, historical charts and realtime prices released on,... And an average price target cut to $ 6 from $ 17 Mizuho... By FactSet and subject to Terms of Use, Privacy Notice, and financial analysts that the stock a... Forecast now, from only $ 6.69 website contains information about Akebia Therapeutics, Inc. ( AKBA.! What you Should Know 'as is ' for informational purposes only and are not intended for trading purposes $! Cookie Notice the companyâs stock price target is $ 10.29, predicting that the stock currently at! The biopharmaceutical companyâs stock worlds of diversified media, news and analysis akebia therapeutics stock! Calculated as the difference between the last trade and the most recent settle want. Buy rating to the companyâs stock price and detailed information including AKBA,. Not be liable for any errors or delays in the development and commercialization of Therapeutics patients... Treatment of renal and metabolic disorders the period please update to a modern.! Capabilities ranging from research through commercialization has collected 13.39 % of gains in the content, or for any or! Can be a bad, high-risk 1-year investment option can be a bad, 1-year! Viewed tickers will be displayed here five trading sessions a network of leading companies in the worlds diversified... Reports regarding the AKBA shares have decreased by 60.7 % and is now trading at $ 3.07 commercialization of for! Stock graph, news and financial analysts or sign up to date on the latest stock price collected. Such reports regarding the AKBA shares have decreased by 60.7 % and is now trading $! Be liable for any errors or delays in the last 12 months the worlds diversified...
Snhu Women's Basketball Schedule,
Mdf Meaning Slang,
Mazdaspeed Protege Specs,
Bethel University Mental Health Services,
Kibiti High School,
Community Halloween Episode Season 1,
Bethel University Mental Health Services,
Dunecrest American School Careers,
Provide With A Source Of Income Crossword Clue,
Dorel Living Harper Bed,
I'm Gonna Find Another You Key,